The University of Miami has entered into an agreement with Heat Biologics, Inc., the leader in the development of gp96-based immunotherapies that activate a patient’s immune system to fight cancer, to license and develop a portfolio of patents leveraging the gp96 platform to target the Zika virus and other infectious diseases. Heat has formed a wholly owned subsidiary, Zolovax, Inc., to focus on the development of gp96-based vaccines targeting Zika, HIV, West Nile, dengue and yellow fever.
The Zika program will be developed at the Miller School of Medicine under the direction of Natasa Strbo, M.D., D.Sc., research assistant professor of microbiology and immunology, who is focused on researching the immune system’s interaction with the placenta. Strbo is also a co-developer of Heat’s gp96 platform and has spent many years advancing the platform as a vaccine against malaria and HIV.
When 6-year-old Justin Matias left the hearing exam room at University of Miami Health System, he got the shock of a lifetime. Having just been fitted with his first pair of hearing aids — his first comment was, "This is awesome! I can hear better!" — he was surprised by family and friends as well as players, alumni and cheerleaders from his favorite team, the Miami Dolphins.
In an historic move, the University of Miami has created a Department of Interventional Radiology, demonstrating its leadership in this versatile therapy. The approval comes after nearly eight years of monumental growth in the field, both in research and clinical applications, at the University of Miami Miller School of Medicine and UHealth - the University of Miami Health System.
Following several months of preparation and two grueling days of evaluations by some of the world’s top medical academicians, Rodrigo M. Vianna, M.D., Ph.D., professor of surgery, Director of Transplant Services and Chief of Liver and GI Transplantation at UM/Jackson Memorial Hospital, has been granted the prestigious Livre-Docência designation.
Greater student-teacher interaction, self-paced learning and improved educational outcomes are among the benefits of the innovative ’Cane Academy program at the University of Miami Miller School of Medicine, according to faculty members who have integrated new concepts into their courses.
The University of Miami Miller School of Medicine made impressive gains in fundraising performance among medical schools, placing in the top 16 percent in the newest Association of American Medical Colleges Development Survey. After analyzing data from 129 institutions for the 2015 fiscal year, the survey showed that the Miller School moved up four spots from 2014, ranking 21st with total private support of $116.5 million.